Squarepoint Ops LLC Has $441,000 Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Squarepoint Ops LLC increased its stake in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 186.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,913 shares of the medical equipment provider's stock after acquiring an additional 39,624 shares during the quarter. Squarepoint Ops LLC owned about 0.14% of AxoGen worth $441,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Koss Olinger Consulting LLC bought a new stake in shares of AxoGen in the 2nd quarter worth approximately $75,000. Lazard Asset Management LLC boosted its stake in AxoGen by 30.1% during the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider's stock worth $93,000 after buying an additional 2,671 shares in the last quarter. Acadian Asset Management LLC bought a new stake in AxoGen in the 2nd quarter valued at $125,000. BNP Paribas Financial Markets raised its stake in shares of AxoGen by 8.6% in the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider's stock valued at $168,000 after buying an additional 1,651 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of AxoGen by 8.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider's stock worth $240,000 after acquiring an additional 2,204 shares during the period. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on AXGN shares. Raymond James started coverage on shares of AxoGen in a research note on Monday, July 1st. They issued an "outperform" rating and a $13.00 target price on the stock. StockNews.com raised AxoGen from a "hold" rating to a "buy" rating in a report on Friday, October 4th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of AxoGen in a research note on Thursday, June 20th. Finally, JMP Securities increased their price objective on AxoGen from $17.00 to $20.00 and gave the stock a "market outperform" rating in a research note on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AxoGen has an average rating of "Buy" and a consensus price target of $13.80.

AxoGen Price Performance

NASDAQ AXGN traded down $0.13 during trading hours on Thursday, reaching $13.60. 198,296 shares of the company's stock were exchanged, compared to its average volume of 398,925. The firm has a fifty day moving average of $12.58 and a 200-day moving average of $9.15. The company has a current ratio of 3.51, a quick ratio of 2.32 and a debt-to-equity ratio of 0.70. AxoGen, Inc. has a one year low of $3.45 and a one year high of $15.08. The stock has a market cap of $594.39 million, a PE ratio of -27.46 and a beta of 1.13.

AxoGen (NASDAQ:AXGN - Get Free Report) last announced its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The company had revenue of $47.91 million during the quarter, compared to analyst estimates of $43.27 million. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. On average, equities research analysts predict that AxoGen, Inc. will post -0.33 earnings per share for the current fiscal year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.